Fresenius SE & Co. KGaA (OTCMKTS:FSNUY) Reaches New 52-Week High – Should You Buy?

Fresenius SE & Co. KGaA (OTCMKTS:FSNUY)’s share price hit a new 52-week high during trading on Wednesday . The stock traded as high as $11.23 and last traded at $11.02, with a volume of 34213 shares trading hands. The stock had previously closed at $11.15.

Analysts Set New Price Targets

Separately, Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of Fresenius SE & Co. KGaA in a report on Monday, February 3rd.

Fresenius SE & Co. KGaA Price Performance

The company has a current ratio of 1.36, a quick ratio of 1.05 and a debt-to-equity ratio of 0.57. The stock has a market cap of $24.11 billion, a PE ratio of 51.38 and a beta of 1.02. The company has a fifty day moving average of $9.95 and a 200-day moving average of $9.38.

Fresenius SE & Co. KGaA (OTCMKTS:FSNUY) last posted its quarterly earnings data on Wednesday, February 26th. The company reported $0.18 earnings per share (EPS) for the quarter. The firm had revenue of $6.01 billion during the quarter. Sell-side analysts expect that Fresenius SE & Co. KGaA will post 0.79 EPS for the current fiscal year.

Fresenius SE & Co. KGaA Company Profile

Fresenius SE & Co KGaA, a health care company, provides products and services for chronically ill patients. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure.